Alpha 2.0
Login Register
» Articles » PMID: 1099823

Control of Adenovirus Acute Respiratory Disease in U.S. Army Trainees

Overview
Journal Yale J Biol Med
Specialty Biology
Date 1975 Jul 11
PMID 1099823
Citations 31
Authors
F H Top Jr
Affiliations
Soon will be listed here.
Abstract

Although limited almost exclusively to military trainees, acute respiratory disease (ARD) caused by adenovirus types 4 and 7 had been the leading cause of hospitalization in U.S. Army personnel. This decrease which resembles influenza in clinical manifestations led to hospitalization of as many as 50% of military trainees in midwinter and imposed a heavy burden on military hospitals and training programs. In studies undertaken from 1965 to 1970, live adenovirus type 4 and subsequently type 7 vaccines were found to be safe and immunogenic and to confer protection against type specific adenovirus ARD. For the past 5 yr. military trainees have been immunized with both adenovirus vaccines during periods of expected adenovirus disease. Since 1966, use of adenovirus vaccines has been monitored through the adenovirus surveillance program which yields weekly data on incidence and etiology of ARD in basic combat trainees. Since 1973, stable adenovirus vaccines have resulted in excellent control of adenovirus ARD. Potential problems with this immunization program are discussed.

Citing Articles

The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.

Wallace R, Bliss C, Parker A Viruses. 2024; 16(6).

PMID: 38932265 PMC: 11209478. DOI: 10.3390/v16060973.

Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8 T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Zheng Y, Lu Z, Ding J, Jiang N, Wang J, Yang J Cancers (Basel). 2022; 14(18).

PMID: 36139670 PMC: 9497125. DOI: 10.3390/cancers14184512.

Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.

Feng F, Wen Z, Chen J, Yuan Y, Wang C, Sun C Viruses. 2022; 14(3).

PMID: 35336927 PMC: 8952777. DOI: 10.3390/v14030520.

Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.

Coughlan L, Kremer E, Shayakhmetov D Mol Ther. 2022; 30(5):1822-1849.

PMID: 35092844 PMC: 8801892. DOI: 10.1016/j.ymthe.2022.01.034.

Advances in Oral Subunit Vaccine Design.

Van der Weken H, Cox E, Devriendt B Vaccines (Basel). 2020; 9(1).

PMID: 33375151 PMC: 7822154. DOI: 10.3390/vaccines9010001.

References
1.
Top Jr F, Grossman R, Bartelloni P, Segal H, DUDDING B, RUSSELL P . Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis. 1971; 124(2):148-54. DOI: 10.1093/infdis/124.2.148. View
2.
Top Jr F, Buescher E, Bancroft W, RUSSELL P . Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis. 1971; 124(2):155-60. DOI: 10.1093/infdis/124.2.155. View
3.
Collis P, DUDDING B, Winter P, RUSSELL P, Buescher E . Adenovirus vaccines in military recruit populations: a cost-benefit analysis. J Infect Dis. 1973; 128(6):745-52. DOI: 10.1093/infdis/128.6.745. View
4.
Levin S, Dietrich J, Guillory J . Fatal nonbacterial pneumonia associated with Adenovirus type 4. Occurrence in an adult. JAMA. 1967; 201(12):975-7. View
5.
Chanock R, Ludwig W, Heubner R, CATE T, Chu L . Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA. 1966; 195(6):445-52. View